Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States

Supplementary Data S1 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States

<p>Detailed information of the EMT network model.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Namhee Kim (14963603) (author)
Altres autors:	Chae Young Hwang (14963606) (author), Taeyoung Kim (14963609) (author), Hyunjin Kim (14963612) (author), Kwang-Hyun Cho (14953801) (author)
Publicat:	2025
Matèries:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Computational Methods Mathematical modeling Drug Targets Gene Regulation Oncogenes & Tumor Suppressors Suppressors of metastasis Systems Biology
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Data S2 from A Cell-Fate Reprogramming Strategy Reverses Epithelial-to-Mesenchymal Transition of Lung Cancer Cells While Avoiding Hybrid States
per: Namhee Kim (14963603)
Publicat: (2025)

Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
per: Gwo Yaw Ho (14961416)
Publicat: (2025)

Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
per: Renumathy Dhanasekaran (14962092)
Publicat: (2025)

Wind Reversals During Morning and Evening Transitions in a Small Valley
per: Rui Zhang (20177106)
Publicat: (2025)

Illustration of dynamic real-time obstacle avoidance.
per: Meiqing Xu (8502255)
Publicat: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
per: Ana Vujovic (15207479)
Publicat: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
per: Yuanqing Ma (15052437)
Publicat: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
per: Yufang Bao (15386826)
Publicat: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
per: Yemin Wang (17315078)
Publicat: (2025)

Supplementary Table 1 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
per: Qin-Shu Li (16990832)
Publicat: (2025)

Supplementary Table 2 from ESRRB Inhibits the TGFβ Signaling Pathway to Drive Cell Proliferation in Cervical Cancer
per: Qin-Shu Li (16990832)
Publicat: (2025)

Supplementary Table 1 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 2 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 3 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 4 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 6 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 7 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 8 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Supplementary Table 9 from ANO1 Reprograms Cholesterol Metabolism and the Tumor Microenvironment to Promote Cancer Metastasis
per: Chun-Miao Deng (15618965)
Publicat: (2025)

Table S7 from Shared Cancer Dataset Analysis Identifies and Predicts the Quantitative Effects of Pan-Cancer Somatic Driver Variants
per: Jakob Landau (14962529)
Publicat: (2025)

Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
per: Guillaume Davidson (14964069)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_dfhbkcub9dm1c8tbmob4o3pk74